News

Strive was designed to evaluate people with a mutation in the CF gene known as G551D. In the study, profound improvements in lung function (forced expiratory volume in

The Phase 3 trial was supported by the results from a cooperative group-sponsored Phase 2 clinical trial evaluating Nexavar in combination with capecitabine in patients with advanced breast

The agreement includes process development, scale-up and manufacturing for pre-clinical studies. OctoPlus evaluated the feasibility of a controlled release formulation that combines a proprietary eye care ingredient of

The trial, which began last month and is scheduled to finish in June 2011, aims to determine whether Antabuse can deplete the pool of residual virus that regular

In the study, consisting of 243 postmenopausal women, nitroglycerin cream demonstrated a capability to increase bone density by about 7% when applied daily to the upper arms for

TRV120027 is a beta-arrestin biased angiotensin II type 1 receptor (AT1R) ligand, the first biased ligand designed to treat patients with AHF. The randomised, placebo-controlled, double-blind, dose-ranging Phase

TXA127 is a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow. Tarix Pharma expects to recruit a

The lab was accredited for being one of a limited number of central labs in the US to meet the rigorous requirements for medical laboratory quality, and competence

The new patent application titled ‘Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer’ gives additional intellectual property protection to the seven antigens used in Immunovaccine’s DPX-0907